Li Xintao, Wang Baojun, Tang Lu, Lang Bin, Zhang Yu, Zhang Fan, Chen Luyao, Ouyang Jinzhi, Zhang Xu
State Key Laboratory of Kidney Disease, Department of Urology, Chinese PLA Medical Academy, Chinese People's Liberation Army General Hospital, Beijing, China.
Macao Polytechnic Institute School of Health Sciences, Macao, China.
Clin Endocrinol (Oxf). 2016 Dec;85(6):954-961. doi: 10.1111/cen.13134. Epub 2016 Jul 27.
Recent studies have identified that the somatic PRKACA L206R mutation can cause cortisol-producing adenomas (CPAs). This study investigated the prevalence and characteristics of PRKACA, GNAS and CTNNB1 mutations in adrenal lesions in patients from a single centre in China.
DESIGN, PATIENTS AND MEASUREMENTS: We sequenced PRKACA, GNAS and CTNNB1 genes in 108 patients, including 60 patients with CPAs (57 with unilateral and three with bilateral adenomas), 13 with nonfunctional adenomas, 12 with adrenocortical carcinomas (ACCs), 15 with primary bilateral macronodular hyperplasia (PBMAH) and eight with aldosterone and cortisol cosecreting adenomas. Mutations in PRKACA, GNAS and CTNNB1 were examined, and clinical characteristics were compared.
Among the unilateral CPAs, we identified somatic mutations in PRKACA (L206R) in 23 cases (40·4%), GNAS (R201C and R201H) in six cases (10·5%), CTNNB1 (S45C, L46P and S45P) in six cases (10·5%) and CTNNB1 plus GNAS in two cases (3·5%). PRKACA and GNAS mutations were mutually exclusive. Among the patients with nonfunctional adenoma, two carried CTNNB1 mutations. Among the patients with ACC, two carried GNAS and CTNNB1 mutations but none carried PRKACA mutations. One patient showed bilateral CPA, and one PBMAH patient carried PRKACA mutations. No mutations in PRKACA, GNAS or CTNNB1 were identified in the eight patients with aldosterone and cortisol cosecreting adenomas. PRKACA-mutant adenomas were associated with young age, overt Cushing's syndrome and high cortisol levels compared with non-PRKACA-mutant or CTNNB1-mutant lesions.
PRKACA mutations are present in CPAs and bilateral adrenal macronodular hyperplasia. PRKACA mutation is associated with more severe autonomous cortisol secretion.
近期研究已确定体细胞PRKACA L206R突变可导致产生皮质醇的腺瘤(CPA)。本研究调查了中国某单一中心患者肾上腺病变中PRKACA、GNAS和CTNNB1突变的患病率及特征。
设计、患者与测量:我们对108例患者的PRKACA、GNAS和CTNNB1基因进行了测序,其中包括60例CPA患者(57例单侧腺瘤和3例双侧腺瘤)、13例无功能腺瘤患者、12例肾上腺皮质癌(ACC)患者、15例原发性双侧大结节性增生(PBMAH)患者以及8例醛固酮和皮质醇共分泌腺瘤患者。检测了PRKACA、GNAS和CTNNB1的突变情况,并比较了临床特征。
在单侧CPA患者中,我们在23例(40.4%)中发现了PRKACA(L206R)体细胞突变,6例(10.5%)中发现了GNAS(R201C和R201H)突变,6例(10.5%)中发现了CTNNB1(S45C、L46P和S45P)突变,2例(3.5%)中发现了CTNNB1加GNAS突变。PRKACA和GNAS突变相互排斥。在无功能腺瘤患者中,2例携带CTNNB1突变。在ACC患者中,2例携带GNAS和CTNNB1突变,但均未携带PRKACA突变。1例患者表现为双侧CPA,1例PBMAH患者携带PRKACA突变。在8例醛固酮和皮质醇共分泌腺瘤患者中未发现PRKACA、GNAS或CTNNB1突变。与非PRKACA突变或CTNNB1突变病变相比,PRKACA突变腺瘤与年轻、明显的库欣综合征和高皮质醇水平相关。
PRKACA突变存在于CPA和双侧肾上腺大结节性增生中。PRKACA突变与更严重的自主性皮质醇分泌相关。